Mintz Levin Represents BG Medicine in Closing of Initial Public Offering
2/10/2011
Boston, MA - Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented BG Medicine (NASDAQ: BGMD) in its initial public offering of 5,750,000 shares of its common stock at a price of $7.00 per share, before underwriting discounts and commissions.
Based in Waltham, Massachusetts, BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostic tests based on biomarkers.
Representing BG Medicine in the IPO were Mintz Levin Corporate Members Bill Whelan and Scott Samuels.
Lazard Capital Markets LLC acted as the sole bookrunning manager for the initial public offering, and Baird and Cowen and Company acted as co-managers.
With one of the largest life sciences practices in the United States, Mintz Levin has represented more than 400 life sciences clients since the industry’s inception in the 1970s. It has been described by Chambers USA as "a leading life sciences brand" and is ranked in the top tier nationally by U.S. News and World Report/Best Law Firms. The firm's life sciences clients include biotechnology, medical device, medical technology, healthcare IT, and pharmaceutical companies; venture capital firms and investment banks; and research institutes and institutions of higher education located throughout the U.S., Europe, Asia, and the Middle East in a broad range of transactional, regulatory, counseling, and intellectual property matters.
